Publications by authors named "Kayan Tsoi"
Article Synopsis
- Drug-drug interactions (DDIs) involving P-glycoprotein (P-gp) can impact medication effectiveness and safety, necessitating careful management in clinical practice.
- This paper outlines a protocol to assess P-gp-related DDIs, combining literature review and expert input to develop management recommendations for clinicians.
- The end goal is to classify P-gp-modulators and substrates, identify clinically significant DDIs, and create practical guidelines based on the assessment findings.
Background: Drug-disease interactions negatively affect the benefit/risk ratio of drugs for specific populations. In these conditions drugs should be avoided, adjusted, or accompanied by extra monitoring. The motivation for many drug-disease interactions in the Summary of Product Characteristics (SmPC) is sometimes insufficiently supported by (accessible) evidence.
View Article and Find Full Text PDFApolipoprotein-E (apoE) plays important roles in neurobiology and the apoE4 isoform increases risk for Alzheimer's disease (AD). ApoE peptides are biologically active and may be produced in the brain. It is unclear if apoE proteolysis is dependent on isoform or AD status and this was addressed here.
View Article and Find Full Text PDF